牛牛AI助理已提取核心訊息
On February 16, 2024, Novavax, Inc. entered into a Termination and Settlement Agreement with Gavi Alliance, effectively terminating their previous Advance Purchase Agreement from May 5, 2021, concerning the supply of Novavax's COVID-19 vaccine. This settlement resolves the arbitration initiated by Gavi against Novavax and releases both parties from all claims related to the agreement. Novavax has agreed to make an initial settlement payment of $75 million, which was paid on February 20, 2024, and will also make deferred payments totaling $400 million through December 31, 2028. These payments can be offset by annual vaccine credits that Gavi may use for qualifying purchases of Novavax's vaccines for low-income and lower-middle-income countries. Additionally, Novavax has granted Gavi a security interest in accounts receivable from the Serum Institute of India under a License and Supply Agreement related to the production of a malaria vaccine, which will continue for the term of the Settlement Agreement. The details of the Settlement Agreement will be included in Novavax's Annual Report on Form 10-K for the year ended December 31, 2023.
On February 16, 2024, Novavax, Inc. entered into a Termination and Settlement Agreement with Gavi Alliance, effectively terminating their previous Advance Purchase Agreement from May 5, 2021, concerning the supply of Novavax's COVID-19 vaccine. This settlement resolves the arbitration initiated by Gavi against Novavax and releases both parties from all claims related to the agreement. Novavax has agreed to make an initial settlement payment of $75 million, which was paid on February 20, 2024, and will also make deferred payments totaling $400 million through December 31, 2028. These payments can be offset by annual vaccine credits that Gavi may use for qualifying purchases of Novavax's vaccines for low-income and lower-middle-income countries. Additionally, Novavax has granted Gavi a security interest in accounts receivable from the Serum Institute of India under a License and Supply Agreement related to the production of a malaria vaccine, which will continue for the term of the Settlement Agreement. The details of the Settlement Agreement will be included in Novavax's Annual Report on Form 10-K for the year ended December 31, 2023.
2024年2月16日，Novavax, Inc.與Gavi Alliance簽訂了終止和和解協議，實際上終止了他們先前從2021年5月5日起的關於Novavax COVID-19 疫苗供應的預購協議。該和解協議解決了Gavi對Novavax發起的仲裁，並免除了雙方與協議有關的所有索賠。Novavax已同意支付7500萬美元的初始和解金，這筆款項已於2024年2月20日支付，還將在2028年12月31日之前支付總額爲4億美元的延期付款。這些款項可以通過年度疫苗抵免抵消，Gavi可以使用這些抵免額度爲低收入和中低收入國家購買符合條件的Novavax疫苗。此外，根據與瘧疾疫苗生產相關的許可和供應協議，Novavax已向Gavi授予印度血清研究所應收賬款的擔保權益，該協議將持續到和解協議的期限。和解協議的細節將包含在Novavax截至2023年12月31日止年度的10-K表年度報告中。
2024年2月16日，Novavax, Inc.與Gavi Alliance簽訂了終止和和解協議，實際上終止了他們先前從2021年5月5日起的關於Novavax COVID-19 疫苗供應的預購協議。該和解協議解決了Gavi對Novavax發起的仲裁，並免除了雙方與協議有關的所有索賠。Novavax已同意支付7500萬美元的初始和解金，這筆款項已於2024年2月20日支付，還將在2028年12月31日之前支付總額爲4億美元的延期付款。這些款項可以通過年度疫苗抵免抵消，Gavi可以使用這些抵免額度爲低收入和中低收入國家購買符合條件的Novavax疫苗。此外，根據與瘧疾疫苗生產相關的許可和供應協議，Novavax已向Gavi授予印度血清研究所應收賬款的擔保權益，該協議將持續到和解協議的期限。和解協議的細節將包含在Novavax截至2023年12月31日止年度的10-K表年度報告中。
有用
沒用